Skip to main content

Home

  • Drug Development
    • Our Pipeline
    • Evaluation Pipeline
    • Inaphaea BioLabs
    • Therapeutic areas
    • Partnering
    • Useful Links
  • News
  • Investors
    • Regulatory News
    • AIM Rule 26
      • Annual and Half Yearly Reports
      • Admission Document & Articles
    • Shareholder communications
    • Investments Calculator
    • Share Alerts
    • Share Series
    • Share price look-up
    • Analyst Research
  • About us
    • Board of Directors and Management Team
    • Strategy and Vision
    • How we work
    • Working with us
    • Collaborative Pipeline
  • Contact us

News

Breadcrumb

  1. News
Category
Image depicts Suzy Dilly, CEO of ValiRx
Articles

Meet the ValiRx team: Dr Suzy Dilly

19 May 2023
BioEurope Spring
News

2023 events round-up: ValiRx and Inaphaea BioLabs

16 May 2023
Kumar Nawani
Articles

Meet the ValiRx team: Kumar Nawani

3 May 2023
Image depicts Suzy Dilly, CEO of ValiRx
News

ValiRx and Physiomics join forces to provide seamless data integration

26 Apr 2023
Dr Andrew Carnegie
Articles

Meet the Inaphaea BioLabs team: Dr Andrew Carnegie

21 Apr 2023
Dr Cathy Tralau Stewart
News

Article by Dr Cathy Tralau-Stewart published by European Pharmaceutical Manufacturer

12 Apr 2023
Zai Ahmad
Articles

Meet the ValiRx team: Zai Ahmad

3 Apr 2023
Suzanne Dilly
News

Spring Budget key messages: R&D tax relief rate

30 Mar 2023
Treasury Connect
News

ValiRx CEO attends Treasury Connect: Life Sciences Conference

30 Mar 2023
Investor Webinar and Q&A held on 8th March 2023.
Videos and audiocasts

ValiRx Investor Webinar Presentation with Q&A held on 8th March 2023

9 Mar 2023
Dr Cathy Tralau Stewart
Articles

International Women’s Day 2023: carving out a career in the life sciences

8 Mar 2023
The team at Inaphaea BioLabs
News

ValiRx bolsters Inaphaea with trio of appointments

6 Mar 2023
Mark Treharne
Articles

Meet the ValiRx team: Mark Treharne

27 Feb 2023
ValiRx - Operational Update Videocast
Videos and audiocasts

Operational Update Videocast

31 Jan 2023

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Next page Next
  • Last page Last
ValiRx PLC

Contact us

ValiRx Plc
Eliot Park Innovation Centre
4 Barling Way
Nuneaton, CV10 7RH
UK

Tel: +44 (0)2476 796496
Email: info@valirx.com

Registered in England and Wales

Company Number: 3916791
VAT Number: 756 3180 24

UK Registered Office Address
Stonebridge House, Chelmsford Road, Hatfield Heath, England, CM22 7BD

Links

  • Drug Development
    • Our Pipeline
    • Evaluation Pipeline
    • Inaphaea BioLabs
    • Therapeutic areas
    • Partnering
    • Useful Links
  • News
  • Investors
    • Regulatory News
    • AIM Rule 26
      • Annual and Half Yearly Reports
      • Admission Document & Articles
    • Shareholder communications
    • Investments Calculator
    • Share Alerts
    • Share Series
    • Share price look-up
    • Analyst Research
  • About us
    • Board of Directors and Management Team
    • Strategy and Vision
    • How we work
    • Working with us
    • Collaborative Pipeline
  • Contact us
Terms and Conditions Privacy Policy Accessibility Compliance Corporate Governance Corporate Social Responsibility

Site and its contents Copyright © ValiRx PLC 2023. All rights reserved.
Website Design and Development by Sciad Communications Ltd